Since the outbreak of COVID-19, Hadassah Hospital is in a key position at the forefront of patient care, research & development, of innovative drug trials finding effective treatment.
Hadassah Hospital in Jerusalem is responding to multiple unprecedented challenges, all at once. The “second wave” pandemic in Israel represents a serious emergency with 164% Intensive Care occupancy for our hospitals.
Thanks to the generosity of our donors, our Hospital has been able to cope with Israel’s most acute cases of the Coronavirus at the quickly established COVID-19 Units at Hadassah. Our current infrastructure continues to be critical for Jerusalem and Israel today.
As Israel and the world learn to live through the pandemic era, Hadassah continues to develop and expand its ongoing activity as a centre of excellence in both research and treatment. Our researchers continue to impress the world with discoveries of novel solutions both to COVID-19 and other diseases and share these around our globe.
Hadassah’s success in research is down to our approach of “translational” medicine, in which Hadassah excels. This is an interdisciplinary method that takes research in the laboratory straight back to the patient-quickly!
Hadassah’s medical experts are “spreading the word from Jerusalem”. Sharing this advanced applied research from Hadassah with a worldwide network of hospitals and communities including the UK, to extend our help and assistance in the fight against Coronavirus. This will have a direct positive impact on the lives of people across the four corners of the world.
Today’s Research is Tomorrow’s Care – some examples of our results over the last 6 months
- The newly established Wohl Centre for Translational Medicine at Hadassah, builds on the extensive R&D infrastructure to improve scientific knowledge about drugs, diseases and their pathways, finding ways to apply this knowledge in a clinical setting to benefit patient care.
- Hadassah participated in a World Health Organisation (WHO) trial with the drug Remdesivir. Other medicines are being tested to stop the formation of the virus, while others block the virus from penetrating to the body’s cells.
- Hadassah researchers and SodaStream engineers unveiled a jointly developed innovative respiratory device creating high-flow oxygen systems to treat COVID-19 that help address the critical need for respirators in hospitals and healthcare facilities.
- Hadassah’s clinical trial enrich COVID-19-specific “T” cells of the immune system from recovered patients to treat patients who are severely ill with the virus. Plasma collected from recovered COVID-19 patients is also used for treatment.
- Hadassah is studying blood samples of COVID-19 to identify biomarkers that make people more susceptible or resistant to the disease.
- More than 30% of COVID-19 patients suffer from blood clots creating lethal blockages in the lungs, kidneys, heart and brain. Hadassah has found the mechanism that causes them. They are now working on a new way to dissolve these blood clots. Hadassah believes if the drug works to reduce blood clots in COVID-19, it will vastly reduce the numbers of patients needing respirators.
With support from our valued donors, we are already saving lives and infra structure around the world to help mitigate the impact of Covid-19
With your help we can ensure that our medical teams have the essential equipment to treat, research and share this information globally including the UK.